Citations 0
Letters to the Editor
March 2001

Treatment of Frey Syndrome With Botulinum Toxin Type F

Author Affiliations

Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001

Arch Otolaryngol Head Neck Surg. 2001;127(3):339-340. doi:

We are writing in regard to the article by Vargas et al1 entitled "A Pilot Study Evaluating the Treatment of Postparotidectomy Sialoceles with Botulinum Toxin Type A [BoNT/A]," which was published in the March 2000 issue of the ARCHIVES. In accordance with the experience of Vargas and colleagues, my coworkers and I recently reported our results using BoNT/F to treat a parotid sialocele.2 Therefore, we believe that BoNT serotypes other than type A should be considered for use in patients who do not respond to treatment with BoNT/A. In 1995, Drobik and Laskawi3 suggested using BoNT/A to treat patients affected by gustatory sweating, or Frey syndrome. The goal was the reduction of facial sweating by the determination of a cholinergic autonomic block.

First Page Preview View Large
First page PDF preview
First page PDF preview